Quality of life as an endpoint in Phase I oncology clinical trials of novel chemotherapy drugs

Abstract

This paper examines the rationale, utility and feasibility of including quality of life as an outcome measure in Phase I trials of new applications of chemotherapy drugs. Typically, Phase I trials in oncology are designed to assess safety and maximal tolerated dose; however, it is argued that when subjectively assessed, self perceived quality of life is as important as physical toxicity. The outcomes of studies that have applied quality-of-life assessment in Phase I trials are reviewed, and recommendations are made for future research based on both methodologic and practical considerations.

Keywords::

• health-related quality of life
• oncology clinical trials
• Phase I trials
• quality of life